ProteqFlu suspension for injection for horses
Company name: Merial Animal Health Ltd
Address: PO Box 327
Sandringham House
Harlow Business Park
Harlow
Essex CM19 5TG
Telephone: Companion Animals 0870 6000123
Production Animals 0800 592699
Fax: 01279 775888
Email: ukenquiry@merial.com
Website: www.merial.com
Suspension for injection for horses. One dose contains Influenza A/equi-2/Ohio/03 [H3N8] recombinant Canarypox virus (vCP2242) ≥ 5.3 log10 FAID50; Influenza A/equi-2/Newmarket/2/93 [H3N8] recombinant Canarypox virus (vCP1533) ≥ 5.3 log10 FAID50.
Adjuvant:Carbomer.
Active immunisation of horses of 4 months of age or older against equine influenza to reduce clinical signs and virus excretion after infection.
Onset of immunity: 14 days after primary vaccination course.
Duration of immunity induced by the vaccination scheme: 5 months after primary vaccination course and 1 year after the third vaccination.
For intramuscular use.
For administration of the vaccine, use sterile and antiseptic-free and/or disinfectant-free material. Shake the vaccine gently before use.
1st scheme – vaccination against equine influenza:
Administer one dose (1 ml of ProteqFlu), by intramuscular injection, preferably in the neck region, according to the following schedule:
- Primary vaccination course: first injection from 5–6 months of age, second injection 4–6 weeks later.
- Revaccination: 5 months after primary vaccination course followed by annual booster injections.
In case of increased infection risk or insufficient colostrum intake, an additional initial injection of ProteqFlu can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 5–6 months of age and 4–6 weeks later followed by revaccination).
2nd scheme - vaccination against equine influenza and tetanus:
Administer one dose (1 ml), by intramuscular injection, preferably in the neck region, according to the following schedule:
- primary vaccination course with ProteqFlu-Te: first injection from 5–6 months of age, second injection 4–6 weeks later.
- Revaccination:
· 5 months after primary vaccination course with ProteqFlu-Te.
· Followed by:
o against tetanus: injection of 1 dose at an interval of maximum 2 years with ProteqFlu-Te.
o against equine influenza: injection of 1 dose every year, alternatively with ProteqFlu or ProteqFlu-Te, respecting an interval of maximum 2 years for the tetanus component.
In case of increased infection risk or insufficient colostrum intake, an additional initial injection of ProteqFlu-Te can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 5–6 months of age and 4–6 weeks later followed by revaccination).
Contra-indications, warnings, etc
For animal treatment only.
There are no contraindications. A transient swelling (max. diameter 5 cm) which regresses within 4 days may appear at the injection site. Pain and local hyperthermia can occur in rare cases. A slight increase in temperature (max. 1.5 °C) may occur for 1 day, exceptionally 2 days. In exceptional circumstances, apathy and reduced appetite may be observed the day after vaccination. In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
Only healthy animals should be vaccinated. Can be used during pregnancy and lactation. Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but at different sites and not mixed with MERIAL’s inactivated vaccine against rabies. Do not mix with any other veterinary medicinal product.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Withdrawal periods
Zero days.
Keep out of the reach and sight of children.
Use immediately after opening.
Store and transport at 2°C – 8°C (in a refrigerator), protected from light. Do not freeze.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.